Natural Compounds Targeting VEGFRs in Kidney Cancer: An In silico Prediction

Öz

Vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), which target angiogenesis by blocking VEGF signaling, are used in the treatment of many cancers including kidney cancer. Despite their efficacy in cancer, serious adverse effects such as hypertension and cardiovascular toxicities remain a clinical challenge. Natural non-toxic compounds targeting VEGFRs might be an alternative to VEGFR-TKIs. In the current study, we screened databases and literature which recommend natural compounds for kidney cancer and found approximately five hundred natural compounds. After screening for toxicity and drug-likeliness properties, fifteen of these compounds remained. Subsequently, we performed molecular docking studies against VEGFR-1 and VEGFR-2 with Lenvatinib, reported to be the most toxic of TKIs, and the fifteen natural compounds. As a result, Polydatin and Plakortide M gave the closest results to Lenvatinib in the interactions of the compounds with VEGFR-1 and VEGFR-2, respectively.

Anahtar Kelimeler

• VEGFR-TKIs
• natural compounds
• kidney cancer
• VEGFR-1 and VEGFR-2
• ADMET
• in silico analysis

Kaynakça

1. del Sol Jiménez M, Garzón SP, Rodríguez AD, 2003. Plakortides M and N, bioactive polyketide endoperoxides from the Caribbean marine sponge Plakortis halichondrioides. J Nat Prod. 66(5):655-661.
2. Du QH, Peng C, Zhang H, 2013. Polydatin: a review of pharmacology and pharmacokinetics. Pharmaceutical biology, 51(11):1347–1354.
3. Erman M, Biswas B, Danchaivijitr P, Chen L, Wong YF, Hashem T, Lim CS, Karabulut B, Chung HJ, Chikatapu C, Ingles S, Slimane K, Kanesvaran R, 2021. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study. BMC Cancer. 21(1):1021.
4. Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M, 2020. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 84:101966.
5. Gao Y, Dai X, Li Y, Li G, Lin X, Ai C, Cao Y, Li T, Lin B, 2020. Role of Parkin-mediated mitophagy in the protective effect of polydatin in sepsis-induced acute kidney injury. Journal of translational medicine, 18(1):114.
6. Haque I, Subramanian A, Huang CH, Godwin AK, Van Veldhuizen PJ, Banerjee S, Banerjee SK, 2017. The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review. Int J Mol Sci. 19(1):107.
7. Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A, Yi C, 2021. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 147(8):2407-2420.
8. Jeong W, Doroshow JH, Kummar S, 2013. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer. 37(3):110-144.

9. Ji H, Zhang X, Du Y, Liu H, Li S, Li L, 2012. Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull. 87(1):50-59.
10. Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I, 2004. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem. 279(34):36148-57.
11. Kang HG, Lee HK, Cho KB, Park SI, 2021. A Review of Natural Products for Prevention of Acute Kidney Injury. Medicina (Kaunas). 57(11):1266.
12. Kinget L, Roussel E, Verbiest A, Albersen M, Rodríguez-Antona C, Graña-Castro O, Inglada-Pérez L, Zucman-Rossi J, Couchy G, Job S, de Reyniès A, Laenen A, Baldewijns M, Beuselinck B, 2021. MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. Cancers (Basel). 13(12):3099.
13. Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, Hicklin DJ, Ellis LM, Gallick GE, 2006. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer. 94(11):1710-7.
14. Lian L, Li XL, Xu MD, Li XM, Wu MY, Zhang Y, Tao M, Li W, Shen XM, Zhou C, Jiang M, 2019. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer. 28;19(1):183.
15. Liu H, Zhao S, Zhang Y, Wu J, Peng H, Fan J, Liao J, 2011. Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to polydatin-induced apoptosis in human nasopharyngeal carcinoma CNE cells. J Cell Biochem. 112(12):3695-3703.
16. Molaei E, Molaei A, Abedi F, Hayes AW, Karimi G, 2021. Nephroprotective activity of natural products against chemical toxicants: The role of Nrf2/ARE signaling pathway. Food Sci Nutr. 9(6):3362-3384.
17. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J, 2018. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension 71(2):e1-e8.
18. Pires DE, Blundell TL, Ascher DB, 2015. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 58(9):4066-4072.
19. Prša P, Karademir B, Biçim G, Mahmoud H, Dahan I, Yalçın AS, Mahajna J, Milisav I, 2020. The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics. Biochem Pharmacol. 173:113551.
20. Rivière C, Papastamoulis Y, Fortin PY, Delchier N, Andriamanarivo S, Waffo-Teguo P, Kapche GD, Amira-Guebalia H, Delaunay JC, Mérillon JM, Richard T, Monti JP, 2010. New stilbene dimers against amyloid fibril formation. Bioorg Med Chem Lett. 20(11):3441-3443.
21. Roskoski R Jr., 2022. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res. 175:106037.
22. Sharma R, Kadife E, Myers M, Kannourakis G, Prithviraj P, Ahmed N, 2021. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J Exp Clin Cancer Res. 40(1):186.
23. Shiyu S, Zhiyu L, Mao Y, Lin B, Lijia W, Tianbao Z, Jie C, Tingyu L, 2011. Polydatin up-regulates Clara cell secretory protein to suppress phospholipase A2 of lung induced by LPS in vivo and in vitro. BMC Cell Biol. 12:31.
24. Simons M, Gordon E, Claesson-Welsh L, 2016. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 17(10):611-625.
25. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209-249.
26. Vural P, 2018. Fizyolojik ve Patolojik Anjiogenezde Vasküler Endotelyal Büyüme Faktörünün Rolü. Türk Klinik Biyokimya Derg. 16(1): 53-62.
27. Wang HL, Gao JP, Han YL, Xu X, Wu R, Gao Y, Cui XH, 2015. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo. Phytomedicine. 22(5):553-559.
28. Wang X, Xie Z, Lou Z, Chen Y, Huang S, Ren Y, Weng G, Zhang S, 2021. Regulation of the PTEN/PI3K/AKT pathway in RCC using the active compounds of natural products in vitro. Mol Med Rep. 24(5):766.
29. Wu MJ, Gong X, Jiang R, Zhang L, Li XH, Wan JY, 2012. Polydatin protects against lipopolysaccharide-induced fulminant hepatic failure in D-galactosamine-sensitized mice. International journal of immunopathology and pharmacology. 25(4):923–934.
30. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D, 2021. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49(W1):W5-W14.
31. Yan JD, Liu Y, Zhang ZY, Liu GY, Xu JH, Liu LY, Hu YM, 2015. Expression and prognostic significance of VEGFR-2 in breast cancer. Pathol Res Pract. 211(7):539-543.
32. Zhang H, Yu CH, Jiang YP, Peng C, He K, Tang JY, Xin HL, 2012. Protective effects of polydatin from Polygonum cuspidatum against carbon tetrachloride-induced liver injury in mice. PLoS One. 7(9):e46574.
33. Zhang M, Zhao Z, Shen M, Zhang Y, Duan J, Guo Y, Zhang D, Hu J, Lin J, Man W, Hou L, Wang H, Sun D, 2017. Polydatin protects cardiomyocytes against myocardial infarction injury by activating Sirt3. Biochim Biophys Acta Mol Basis Dis. 1863(8):1962-1972.